Ex-Dividend Reminder: John Wiley & Sons, Xcel Energy and Zimmer Biomet Holdings

John Wiley & Sons (WLY), Xcel Energy (XEL) and Zimmer Biomet (ZBH) go ex-dividend on 12/30/2025 with quarterly payments of $0.355 (WLY, payable 1/15/26), $0.57 (XEL, payable 1/20/26) and $0.24 (ZBH, payable 1/30/26). Based on the cited recent WLY price of $31.31 the piece estimates one-day ex-dividend price impacts of approximately -1.13% (WLY), -0.77% (XEL) and -0.27% (ZBH), and annualized yields of ~4.54% (WLY), 3.08% (XEL) and 1.06% (ZBH). Intraday share movements were minimal and the story is primarily informational for dividend-focused positioning rather than a material catalyst for broader markets.

Analysis

Market structure: the immediate mechanical impact is small — WLY (-1.13%), XEL (-0.77%), ZBH (-0.27%) on ex-div dates — but the deeper winners are income-seeking allocators and regulated-utility balance-sheet owners (XEL) while cyclical med‑tech (ZBH) is more exposed to elective-surgery cycles and pricing pressure. Yield scarcity channels incremental flows into utilities and high-yield names (WLY 4.54%, XEL 3.08%), tightening bid for those stocks and compressing spreads vs. investment-grade corporates if rates remain stable.

Risk assessment: tail risks include adverse PUC rulings or a +50–100bps move in 10‑yr yields that would reprice utility multiples, major academic subscription declines hitting WLY, or litigation/recall for ZBH; these are low-probability but high-impact over 6–36 months. Short-term (days/weeks) expect only ex-div mechanical moves and potential tax-window trading; medium-term (3–12 months) dividend sustainability and capital allocation (buybacks/debt) will matter most.

Trade implications: tactical positions favor XEL for stable cash flows (12–24 month hold) and selective WLY exposure for income/duration if one accepts publishing secular risk; prefer hedged short or put-spread exposure to ZBH for 6–9 months given low dividend support (1.06%) and higher operational cyclicality. Options: use covered-call overlays on XEL (sell ~3% OTM 3–6 month calls) to boost yield, and buy 3–6 month 0.25‑delta puts on WLY as downside protection when initiating longs.

Contrarian angles: consensus understates WLY’s pricing power in core academic niches — if subscription renewals hold, upside is underappreciated and dividend yield is a support; conversely, XEL’s regulatory safety is rate-sensitive and would be meaningfully repriced if the 10‑yr breaches ~4.0% (reduce exposure). ZBH’s low yield suggests limited investor protection — a contrarian buy only on clear evidence of margin recovery or a >20% pullback offering asymmetric reward-to-risk.

Key Decisions for Investors

• Establish a 2–3% portfolio long in XEL for a 12–24 month horizon to capture 3.08% yield + regulated rate‑base growth; sell 3–6 month covered calls ~3% OTM to boost near-term income, and trim to zero if 10‑yr Treasury >4.0% or XEL total return lags sector by >10% over 3 months.
• Initiate a 1–2% position in WLY for income and potential recovery over 12 months, paired with 3–6 month protective puts (~0.25 delta) sized at 25–50% of the equity position to limit downside from subscription deterioration.
• Take a tactical 1–2% short or bearish put‑spread on ZBH for 6–9 months (buy ~0.25 delta put, sell ~0.12 delta put) to express cyclicality and weak dividend support; close or flip if ZBH margin expansion >200bps or share price gaps down >20% (re-evaluate).
• Run a relative-value pair trade: long XEL / short ZBH (1:1 weight) for 6–12 months sized 2% net exposure to capture defensive/regulatory vs cyclical divergence; rebalance if the spread between holdings changes by >6 percentage points or macro catalysts (PUC decision, Medicare policy) occur.